ABSTRACT
Metronomic chemotherapy has emerged as a compelling and innovative therapeutic approach in the management of breast cancer. This chapter highlights the application of metronomic chemotherapy especially in the context of breast cancer treatment. Administering low-dose chemotherapeutic agents at regular intervals has given us promising results. The chapter also gives insights into the underlying mechanisms of metronomic chemotherapy in breast cancer, including its role in inhibiting angiogenesis. The chapter also discusses the recent clinical trials that have investigated the efficacy of metronomic chemotherapy in breast cancer patients, highlighting its potential to prolong disease stabilization, mitigate drug resistance, and improve patient quality of life. Furthermore, the challenges and limitations of implementing metronomic chemotherapy in clinical practices, such as the need for tailored treatment regimens and identification of optimal patient populations, are also discussed in the chapter. As a versatile and less toxic treatment option, metronomic chemotherapy has the potential to revolutionize the landscape of breast cancer therapy, offering a novel approach that enhances treatment efficacy while minimizing side effects.
